posted on 2015-05-28, 14:16authored byObolbek Turapov, S. J. Waddell, Bernard Burke, Sarah Glenn, Asel A. Sarybaeva, G. Tudo, G. Labesse, D. I. Young, M. Young, Peter W. Andrew, P. D. Butcher, M. Cohen-Gonsaud, Galina V. Mukamolova
Antimicrobials targeting cell wall biosynthesis are generally considered inactive against nonreplicating bacteria. Paradoxically, we found that under nonpermissive growth conditions, exposure of Mycobacterium bovis BCG bacilli to such antimicrobials enhanced their survival. We identified a transcriptional regulator, RaaS (for regulator of antimicrobial-assisted survival), encoded by bcg1279 (rv1219c) as being responsible for the observed phenomenon. Induction of this transcriptional regulator resulted in reduced expression of specific ATP-dependent efflux pumps and promoted long-term survival of mycobacteria, while its deletion accelerated bacterial death under nonpermissive growth conditions in vitro and during macrophage or mouse infection. These findings have implications for the design of antimicrobial drug combination therapies for persistent infectious diseases, such as tuberculosis.
Funding
The study was supported by the Wellcome Trust (GM 081396/Z/06/Z,
WT097828MF); BBSRC (O.T., D.I.Y., and M.Y.; P15165); European
Union “New Medicines for TB—NM4TB” (LSHP-CT-2005-018923);
Ministerio de Educación y Ciencia, Spain (G.T.; 2005/0565); the Schlumberger
Foundation (A.S.); and the French Infrastructure for Integrated
Structural Biology (M.C.G.; ANR-10-INSB-05-01).
History
Citation
Antimicrobial Agents and Chemotherapy, 2014, 58 (5), pp. 2798-2806
Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Infection, Immunity and Inflammation